Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alimera Sciences, In (ALIM)
1.44 ? 0.04 (2.86%)
Volume: 144,601 @ 4:00:00 PM ET
Bid Ask Day's Range
1.11 1.96 1.4 - 1.46
ALIM Detailed Quote
ALIM News: Statement of Changes in Beneficial Ownership (4) 03/13/2017 04:57:48 PM
ALIM News: Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain 03/13/2017 07:30:00 AM
ALIM News: Alimera Sciences to Present at the 29th Annual ROTH Conference 03/07/2017 07:30:00 AM
ALIM News: Annual Report (10-k) 03/03/2017 04:23:40 PM
ALIM News: Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference 03/03/2017 10:05:00 AM
Alimera Sciences, In (ALIM)
1.44 ? 0.05 (3.60%)
Volume: 486,030 @ 5:52:02 PM ET
Bid Ask Day's Range
1.38 1.46 1.321 - 1.45
ALIM Detailed Quote
Yep. Come on .50
I might be right, .50
I was hoping for .50
Yep. $$$$$ Go Big !!!
Carl,
Hitting $2.00 tomorrow or Mon. Last year some big boys Cap. Companies were loading this stock. Don't be surprised to see $3. to $5. in the next months. They are expanding there distribution network with an excellent eye product. Time to make MONEY.........
Haha keep raising your pt. Stock up 20% plus since you've been bashing. I sold yesterday though lol.
.25 come on let's go ! Down !
Yes it is, for longs
Looking good Lol
Raised from .00001? Haha how's that short working out
You know the zero's Lol.
your here? i guess i dont need to look at this stock lol
Downward trend .0001
Hey guys havent folowed this one in a while. Looks like its built a nice base. Should I be jumping in now? Any recent news? Its down a lot over the years.
Hey why so quiet today?
ALIM News: Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada 08:00 AM
ALIM News: Statement of Ownership (sc 13g) 02/14/2017 06:11:52 PM
ALIM News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 05:43:53 PM
ALIM News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 03:02:00 PM
ALIM News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 08:08:06 AM
News News Alert: Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada 02/22/2017 08:00:00 AM
Alimera Sciences, In (ALIM)
1.4399 ? 0.1899 (15.19%)
Volume: 3,720,332 @ 11:52:40 AM ET
Bid Ask Day's Range
1.42 1.44 1.25 - 1.45
ALIM Detailed Quote
Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada
http://ih.advfn.com/p.php?pid=nmona&article=73923580
[-chart]resource.globenewswire.com/Resource/Download/a0fc0818-863a-4533-89c5-56e1bff5632e?size=2[/chart]
Date : 02/22/2017 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Alimera Sciences, Inc. (MM) (ALIM)
Quote : 1.25 0.0 (0.00%) @ 8:11AM
Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, and Knight Therapeutics Inc. (TSX:GUD) (Knight), a leading Canadian specialty pharmaceutical company, today announced that Knight’s New Drug Submission (NDS) for ILUVIEN® has been accepted for review by Health Canada. ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is Alimera's sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure
“ILUVIEN is a unique and innovative product that is available in different markets around the world, including the U.S. and Europe,” said Jonathan Ross Goodman, CEO of Knight. “We are happy to continue advancing ILUVIEN and our portfolio of novel therapeutics that improve the health of Canadian patients.”
“This is another important milestone for ILUVIEN,” said Dan Myers, CEO of Alimera. “We believe ILUVIEN is the only therapy that treats DME consistently every day due to its continuous microdosing for up to three years, and we look forward to working with Knight and Health Canada to make ILUVIEN available to Canadian patients.”
Knight and Alimera signed an agreement in July 2015 granting Knight the exclusive right to distribute ILUVIEN in Canada.
About ILUVIEN
http://www.ILUVIEN.com.
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.
About Alimera Sciences, Inc.
http://www.alimerasciences.com
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit
http:// www.alimerasciences.com.
Alimera Forward Looking Statements
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s plans to make ILUVIEN available to Canadian patients. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Knight’s ability to obtain approval from Health Canada and to launch ILUVIEN in Canada, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarters ended June 30, 2016 and September 30, 2016, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at http://www.sec.gov. Additional factors may also be set forth in those sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2016, to be filed with the SEC in the first quarter of 2017. In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight's shares trade on TSX under the symbol GUD. For more information about Knight, please visit the company's web site at www.gud-knight.com or www.sedar.com.
Knight Forward-Looking Statement
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
For Alimera Sciences:
Katie Brazel
404-317-8361
kbrazel@bellsouth.net
For Knight Therapeutics:
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-GUD1 (4831)
info@gud-knight.com
Primary Logo
///////////////////////////////////////////////////////////////
previous/
good morning, news/ Alimera Sciences Begins Selling ILUVIEN® in the Middle East
http://finance.yahoo.com/news/alimera-sciences-begins-selling-iluvien-113000658.html
GlobeNewswire•October 26, 2016
ATLANTA, Oct. 26, 2016 (GLOBE NEWSWIRE)
-- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that its subsidiary, Alimera Sciences B.V.,
has begun shipping ILUVIEN®,
an eye implant for the treatment of diabetic macular edema (DME),
to MEAgate International FZLLC, headquartered in Dubai, for Named Patient Sales in the Middle East.
MEAgate is the ILUVIEN distributor for
Bahrain,
Egypt,
Iraq,
Jordan,
Kuwait,
Lebanon,
Oman,
Qatar,
Saudi Arabia,
UAE, and
Yemen,
where combined an estimated 16 million people today are living with diabetes.
Following the successful completion of a technical review,
the Health Authority
- Abu Dhabi (HAAD) code for ILUVIEN was published on October 11, 2016.
The HAAD code allows for the reimbursement of ILUVIEN by HAAD.
In addition, some large Middle East institutions are finalizing compassionate use programs in order to include ILUVIEN in their available treatment options.
The first DME patient in the region was treated with ILUVIEN
under the Named Patient Sales program,
an early access program whereby health authorities allow selected institutions to provide globally approved innovative medications
to their patients while the products are still in the process of approval and full registration.
“Diabetes and its complications have been listed among the top priorities of health authorities across the region,”
said Dream Samir, MEAgate’s chief executive officer.
“In several Middle-East countries,
prominent ophthalmologists have confirmed that ILUVIEN will address
an unmet need for a significant number of their patients with diabetes.”
“We are pleased to begin providing ILUVIEN to this population,”
said Dan Myers,
Alimera’s chief executive officer.
“Given the high incidence of diabetes in the region,
we believe a continuous microdosing delivery system will be welcomed
by both retinal specialists and their patients with diabetic macular edema.”
About ILUVIEN
www.ILUVIEN.com.
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant approved in the U.S.
to treat diabetic macular edema in patients who have been
previously treated with a course of corticosteroids and did
not have a clinically significant rise in intraocular pressure.
Each ILUVIEN implant is designed to release submicrogram levels
of fluocinolone acetonide, a corticosteroid, for 36 months.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy,
is a disease affecting the macula, the part of the
retina responsible for central vision.
When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME.
The onset of DME is painless and may go unreported by the patient
until it manifests with the blurring of central vision or
acute vision loss.
The severity of this blurring may range from mild to profound loss of vision.
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people
with diabetes included in the study were diagnosed with DME.
All people with type 1 or type 2 diabetes are at risk of developing DME.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
Alimera is presently focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.
Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed
to treat early- and late-stage diseases.
For more information, please visit
http://www.alimerasciences.com.
About MEAgate International FZ LCC
The management team of MEAgate includes seasoned pharmaceutical
and
life sciences executives with over 35 years combined experience
in selling pharmaceuticals and medical devices in much of the Middle East.
They have developed a Middle East hub to address the needs of small
to medium innovative companies,
and become the partner of choice that ensures highest scientific
and compliant standards while managing
– on behalf of the company
– a network of carefully chosen country distributors.
Teams are centrally selected, hired and trained, ensuring that the same high standards are applied across the region.
Oh, I know I'm just messing around too, wanted to see if I could get a logical sentence out of him lol! Agree, loving this setup!
I'd recommend you stop wasting energy on this clown. He's obviously just screwing with you. Alimera is currently one of the best values I've ever seen in small cap bio land. Big time winner this year. Just ignore the noise and wait for payday.
Co has over $30m in cash.
Co looking for money!
Who will get the last laugh. .01
Hahahaha. Check back next week. You're not even short, just a troll. Too funny ;)
Debt . Lower we go .
MM's tested supply today, very low volume selling at resistance. They are ready to move it north. Fundamentals and technicals are saying it's moving north. Now, do you have a response with actual facts, data, or anything?
Going below a dollar.
I don't get it? Are you short, just trying to bash? Would you like to have an intelligent discussion or response to my post? Or just post more one liner bashing comments?
You posting on the right ticker?
Look at the action today too, it can't be more obvious. 600k it the ask around noon and it didn't move the price. The price went down on a 300 and 141 share trade. Hahahaha
You do realize this is currently over 80% institutional owned right? The price is being controlled. It will be going north in short time
Yep head fake! .0001
Followers
|
33
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1033
|
Created
|
12/26/10
|
Type
|
Free
|
Moderators |
Alimera Sciences, Inc. (Alimera) is committed to conducting its business in compliance with all applicable laws, rules, and regulations and the highest standards of ethical conduct. To this end, we have established and will maintain a Comprehensive Compliance Program (“Compliance Program”) in accordance with the OIG Compliance Program Guidance for Pharmaceutical Manufacturers (the “OIG Guidance”) published by the Office of Inspector General, U.S. Department of Health and Human Services. Our Compliance Program is a key component of our commitment to adhering to the highest standards of corporate responsibility and fostering a culture of compliance that places a premium on doing business with integrity. Our Program also incorporates the Code on Interactions with Healthcare Professionals published by the Pharmaceutical Research and Manufacturers of America.
We have designed our Compliance Program to (1) prevent, detect, and remediate violations of applicable laws, rules, and regulations, as well as Alimera’s policies and procedures and (2) promote a culture of the highest ethics within the company. It is Alimera’s expectation that employees will comply with our Code of Business Conduct and the policies and procedures established in support of that Code. As the OIG Guidance recognizes, however, the implementation of a Compliance Program cannot guarantee the elimination of improper employee conduct.
As recognized in the OIG Guidance, we have tailored our Compliance Program — the fundamental elements of which we have described below – to fit the unique environment of our company. Moreover, our Compliance Program is dynamic and we regularly review and enhance our Program to meet our evolving compliance needs.
You may obtain a copy of this Compliance Program description by calling 1-844-445-8843.
Compliance Officer. Alimera has appointed a Compliance Officer who is charged with developing, implementing, and monitoring the Compliance Program. We will ensure that the Compliance Officer has the ability to exercise independent judgment and, as necessary, effectuate change within the company. The Compliance Officer reports to the President and Chief Executive Officer of Alimera, is a member of Alimera’s Executive Management team, and has direct access to the Alimera Board of Directors.
Compliance Committee. Alimera has established a Compliance Committee made up of Alimera senior management. The role of the Compliance Committee is to advise and assist the Compliance Officer in the development, implementation, and ongoing oversight of the Compliance Program. The Compliance Committee meets on a regular basis to identify and manage areas of risk and areas of critical focus for the Compliance Program.
Alimera has established written policies and procedures, including our Code of Business Conduct, which articulates our fundamental principles and values and provides a framework for ethical conduct within our company. The Code of Business Conduct establishes our expectation that management, employees, and agents of Alimera act in accordance with all applicable laws, rules, and regulations; Alimera’s policies and procedures; and the highest standards of ethics.
In accordance with California law, Alimera has established an annual spending limit for certain promotional activities directed toward healthcare professionals who prescribe or may influence prescribing in California. At the present time our annual, per-prescriber spending limit is $1,500. Examples of items that fall within this spending limit are occasional modest meals in connection with informational presentations and educational items.
This annual spending limit does not include payments to healthcare professionals for bona fide consulting or other services.
It is Alimera’s policy to not provide any item of value to any healthcare professional with the intent of influencing that healthcare professional’s prescribing habits.
A crucial element of our Compliance Program is the education and training of our employees on their legal and ethical obligations under applicable laws, rules, regulations, and company policies and procedures. Alimera regularly communicates our policies and procedures to promote a thorough understanding of the company’s expectations and regularly reviews and updates our training initiatives.
Alimera actively fosters dialogue between management and employees. Our goal is that all employees should know to whom to turn when seeking answers to questions or reporting possible violations of company policies or procedures, and understand that they can make such reports without fear of retaliation. To that end, we have adopted open-door and non-retaliation policies. We have a toll-free compliance helpline to which employees of Alimera may anonymously raise questions or report any concerns or suspected violations of applicable laws, rules, regulations, or Alimera policies or procedures.
Alimera’s Compliance Program includes monitoring and auditing to evaluate adherence to Alimera’s policies and procedures.
We note that, in accordance with the OIG Guidance, the nature, extent, and frequency of our compliance monitoring and auditing
may vary according to new regulatory requirements, changes in business practices, and other considerations.
When Alimera becomes aware of potential violations of applicable laws, rules, or regulations or company policies or procedures,
the company will promptly investigate such matters and make a determination as to whether the facts substantiate the existence of a violation.
Alimera will document the conduct of such investigations.
While each substantiated violation will be considered on a case-by-case basis, where appropriate we will utilize disciplinary action consistent
with company policy to address violative conduct and to deter future violations.
We will also work to determine the root cause of the violation and assess whether the violation is due to gaps in company policies or procedures
and take appropriate corrective action designed to prevent future violations.
Alimera Sciences, Inc. hereby declares that, to the best of our knowledge, information, and belief,
and based upon our good-faith understanding of the statutory requirements, we have, as of March 3, 2015,
established a Comprehensive Compliance Program that is in material compliance with the requirements of California Health and Safety Code §§ 119400-119402.
While Alimera’s Comprehensive Compliance Program cannot completely eliminate the possibility that an individual employee will engage in improper conduct,
our Program is reasonably designed to prevent and detect violations of applicable laws, rules, and regulations, as well as our own internal policies and procedures.
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |